AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7

Percentage of participants achieving a ≥ 2-grade improvement from baseline on the FWS according to investigator assessments of GL severity at maximum frown at any postintervention timepoint through Day 7 were reported. Investigators' assessments of the severity of GL at rest and maximum frown using the validated FWS was assessed using the 4-grade FWS, where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame: Baseline (Day 1) through Day 7

Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. TEAEs were defined as events event began on or after the date and time of the study intervention; or the adverse event was present before the date and time of the study intervention, but increased in severity or became serious on or after the date and time of the study intervention.

Time frame: From first dose of study drug until the end of study (up to 42 days)

Number of Participants With Potentially Clinically Significant Laboratory Parameters Post Intervention

Potentially clinically significant post intervention laboratory values included hematology, chemistry, and urinalysis as defined in the SAP.

Time frame: From first dose of study drug until the end of study (up to 42 days)

Number of Participants With Potentially Clinically Significant Vital Signs Post Intervention

Potentially clinically significant post intervention vital sign measurements included systolic and diastolic blood pressure, pulse rate, respiration rate, body temperature as defined in the SAP.

Time frame: From first dose of study drug until the end of study (up to 42 days)